Compare NEWP & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEWP | SPRY |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 777.3M | 796.4M |
| IPO Year | 2006 | 2020 |
| Metric | NEWP | SPRY |
|---|---|---|
| Price | $4.02 | $8.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $40.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.9M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.36 | $6.66 |
| 52 Week High | $6.31 | $18.63 |
| Indicator | NEWP | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 40.84 |
| Support Level | $3.93 | $7.39 |
| Resistance Level | $5.19 | $8.61 |
| Average True Range (ATR) | 0.29 | 0.61 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 25.91 | 16.32 |
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.